Cash Flow Statement

Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Traws Pharma (TRAW) Cash from Investing Activities (2019)

Traws Pharma (TRAW) has disclosed Cash from Investing Activities for 4 consecutive years, with $1000.0 as the latest value for Q4 2019.

For Q4 2019, Cash from Investing Activities changed N/A year-over-year to $1000.0; the TTM value through Dec 2023 reached $1000.0, changed N/A, while the annual FY2025 figure was -$2.6 million, 29.14% up from the prior year.
Cash from Investing Activities hit $1000.0 in Q4 2019 for Traws Pharma, down from $15.0 million in the prior quarter.
Across five years, Cash from Investing Activities topped out at $1000.0 in Q4 2019 and bottomed at $1000.0 in Q4 2019.